Healthcare AI startup OpenEvidence has raised $250 million in funding, lifting its valuation to $12 billion, SiliconANGLE reported on Jan. 21 local time.

Thrive Capital and DST Global participated in the investment. OpenEvidence has raised its valuation more than tenfold since its first funding round last year.

OpenEvidence provides a ChatGPT-style research tool for clinicians. The AI searches medical journals, suggests diagnosis and treatment options, and helps users track changes to the latest treatment guidelines.

OpenEvidence CEO Daniel Nadler (다니엘 나들러) said, "Doctors need 9 hours a day to keep up with new medical information." He said that without OpenEvidence, the risk of missing important discoveries is high.

The OpenEvidence platform is also used for medical education. Medical schools use it to generate exam questions, and students can use it as a study aid. The AI provides suitable answers tailored to various clinical specialties and secures clinical data through cooperation with medical journals and associations.

OpenEvidence runs an advertising-based revenue model and plans to diversify revenue by developing additional medical applications. It recently launched a medical record-writing tool and can compete with OpenAI's ChatGPT Health feature. The latest funding will be used for research and development and to expand computing infrastructure.